Ocrelizumab (Ocrevus)

Provider Order Form rev. 08/06/2025



PATIENT INFORMATION		Referral Status	s: 🗆 New Re	eferral 🗆	Updated Ord	ler 🗆 (Order Renewal
Patient Name:			DOB:		Patient Pho	ne:	
Patient Address:				Patient	: Email:		
Allergies:			☐ NKDA Weight (lbs/kg): Height (in/cm):				
Sex: □ M / □ F Date of Last Infusion: Next Due			te:	Preferre	d Location:		
DIAGNOSIS (Please provide	e ICD-10 code in spac	ce provided)					
☐ G35: Multiple Sclerosis	·	•					
Type: □ R	RMS 🗆	SPMS	□ PPMS		PRMS		CIS
☐ Other: D	escription:						
THERAPY ADMINISTRATION & DOSING ☐ Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose ☐ Maintenance: Administer Ocrevus 600 mg IV in 500 ml 0.9% normal saline every 6 months ☑ Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS LABORATORY ORDERS			PRE-MEDICATION ORDERS ☐ Tylenol 500mg ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP ☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP ☐ Solumedrol 125mg IVP ☐ Other: ☐ Wurst have negative hepatitis B and TB test prior to start ☐ Hold infusion and notify provider for: ☐ Signs/symptoms of infection or planned/recent surgery. ☐ recent live vaccines ☐ pregnancy or neurological symptoms. ☐ Monitor vital signs with every rate change, then every 30 minutes and prior to discharge.				
□ CBC w/ diff □ at each □ Quantitative Serum Immune □ Other: □ PROVIDER INFORMATION	Globulin every 3 mor		☑ Patients or serious infusi be eligible for specifics on e ☑ Provide nu	n maintenan on reaction v r an increase digibility and dirsing care pe vity Reaction	ce dosing who with any previ	ous Ocreve. Referenable. Cedure, ir	-
Preferred Contact Name:			Preferred Contact Email:				
Ordering Provider:	-			vider NPI:			
Referring Practice Name:			hone:		Fax:		
Practice Address:		C	ity:	State	2:	Zip C	lode:
REQUIRED DOCUMENTA		•					
Required Documentation: Pat treatment failures or contraine Required Labs: Negative Hepa	dications, MRI result		primary and s	econdary in	surance, 2 m	ost recen	t OVN including
Provider Name (print) Provider Signat			re			Date	

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.

Disclaimer: By signing this form, I authorize Novella Infusion and its affiliates to act as my designated agent in submitting prior authorizations, financial assistance applications, and other clinically required information with respect to this patient and order. This enrollment form shall serve as my signature for prior authorizations and financial assistance programs, as requested.